They are buying a crown jewel and they are getting it at a reasonable valuation.
When you have a look at the potential liability they have in infringement cases, you basically could save multiple billions of dollars.
If the deals went to shareholders today, we believe Boston Scientific would prevail.
The fact that they found something else is not a concern. It's almost to be expected. When a policeman pulls you over for speeding and decides to look around your car, there's a good likelihood that if he wants to, he can find something to give you a citation for.
While it could be a knock-out blow, at what point are we overpaying? I think we could be getting close to that point based on the cardiac rhythm business.
It they found somebody who could clean up ship a little, it sends a message.
This is a very simple integration. It should not be difficult.
The deal will proceed if J&J will get the price it wants. I am not sure Guidant will give them that price.
This offer is superior. This offer promises a higher price, stock with better appreciation potential, commitments to do what it takes to avoid antitrust concerns, and a firm timeline.
We expect prices to continue to decline. Leverage helps on the way up and it hurts on the day down. Boston Scientific recognizes it and that's why they want Guidant.
